相关实验视频

Updated: Jul 18, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

[ESR1突变阳性复发性乳腺癌成功用莱特醇加阿贝马西克利布治疗]

Risa Terasawa¹, Yuko Takashima, Aoko Hirata

¹Dept. of Breast and Endocrine Surgery, Hirakata City Hospital.

Gan to kagaku ryoho. Cancer & chemotherapy

|August 23, 2023

概括

雌激素受体阳性乳腺癌通常由于ESR1突变而对内分泌疗法产生抵抗力. 这项病例研究显示,尽管存在ESR1突变,但对莱特醇加上abemaciclib的长期反应.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

雌激素受体 (ER) 阳性乳腺癌约占病例的70%,需要内分泌治疗.
内分泌疗法是ER阳性转移性或复发性乳腺癌的主要治疗方法,但耐药性往往会发展.
ESR1基因突变是内分泌耐药性的关键机制,特别是在长期使用芳酶抑制剂 (AI) 治疗后.

研究的目的:

报告一个成功长期治疗ER阳性转移性乳腺癌的病例,使用AI加abemaciclib,尽管存在ESR1突变.
审查关于管理ESR1突变的内分泌耐药乳腺癌的文献.

主要方法:

这项研究涉及一个ER阳性转移性乳腺癌患者的病例报告.
进行基因查以确定ESR1突变.
治疗包括芳香酶抑制剂 (莱特) 与abemaciclib.lib.结合使用.
对相关病例和治疗策略进行了文献审查.

主要成果:

尽管确认了ESR1突变阳性,但患者实现了长期部分响应 (PR).
莱特醇和abemaciclib的组合在克服由ESR1突变介导的内分泌抵抗方面表现出有效性.
案例突出了一个潜在的治疗策略,对于一个具有挑战性的乳腺癌患者的子集.

结论:

与芳酶抑制剂和abemaciclib联合治疗可以在ER阳性转移性乳腺癌中有效治疗ESR1突变.
当与向药物结合时,ESR1突变不一定会排除成功的基于内分泌的治疗.
需要进一步的研究来探索abemaciclib在ESR1突变乳腺癌中的作用.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...